Emphysema News and Research

Latest Emphysema News and Research

French Ministry of Health approves cost-effectiveness study of RePneu Lung Volume Reduction Coil

PneumRx, Inc., a leader in the field of interventional pulmonology, today announced that the French Ministry of Health has approved a cost-effectiveness study of the RePneu Lung Volume Reduction Coil in France.

30 Jul 2012

Hypoxic lung environment increases HIF-2a tumor growth signaling

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

25 Jul 2012

Viewpoints: Cutting health costs is next battle; Texas Medicaid chief on why expansion won't work; Grief, anger over end-of-life decision

No matter what happens to President Obama's health care reforms after the November elections, the disjointed, costly American health care system must find ways to slow the rate of spending while delivering quality care. There is widespread pessimism that anything much can be achieved quickly, but innovative solutions are emerging in unexpected places. A health care system owned and managed by Alaska's native people has achieved astonishing results in improving the health of its enrollees while cutting the costs of treating them.

24 Jul 2012

FDA approves Forest Laboratories’ Tudorza Pressair to treat COPD

Forest Laboratories, Inc. and Almirall, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved Tudorza Pressair (aclidinium bromide inhalation powder) for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Researchers discover potential drug targets that might reduce ventilator-induced lung inflammation

When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.

19 Jul 2012

Nicotine addiction: An interview with Dr. Crystal

Cigarette smoking and nicotine addiction are widespread problems throughout the world. Many people continue to smoke despite high taxes and the available public information on the dangers of smoking.

3 Jul 2012

USPTO issues patent to Aeris’ cross-linked polymers for treatment of emphysema

Aeris Therapeutics, LLC announced that the U.S. Patent and Trademark Office has issued a patent covering the use of cross-linked polymers administered into the lung to reduce lung volume for the treatment of emphysema.

14 Jun 2012

Inexpensive paper-based device warns about unhealthy levels of airborne metals

Scientists are reporting development of a new paper-based device that can warn workers that they are being exposed to potentially unhealthy levels of airborne metals almost immediately, instead of the weeks required with current technology. The report on the device, which costs about one cent to make and could prevent illness in the millions of people who work with metal, appears in ACS' journal Analytical Chemistry.

1 Jun 2012

LVRC safe and effective choice for patients with severe heterogeneous emphysema

A tiny, resilient metal wire designed to gather and compress diseased lung tissue may offer relief to patients with severe heterogeneous emphysema, a subtype of the disease that involves specific, usually isolated areas of the lungs, according to the results of a multicenter international trial conducted in the Netherlands, Germany and France. The wire, called a lung volume reduction coil (LVRC), can be easily implanted and is designed to take the place of more invasive procedures used to improve the lung function of emphysema patients.

24 May 2012

Combination of Chartis system and Zephyr EBV treatment effective in treating emphysema

Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the Chartis Multi-Centre study. The study is the first to combine the Chartis Pulmonary Assessment System and Zephyr EBV treatment for patients with advanced emphysema.

11 May 2012

Cardiac testing important for lung disease prognosis, treatment

A simple test for heart disease risk can go a long way toward determining the long-term prognosis for people with chronic obstructive pulmonary disease, according to UC Irvine researchers.

3 May 2012

One organ donor can save up to eight lives

Judy Weimer, 53, was diagnosed with COPD, emphysema and bronchitis on New Year's Eve in 2005 and received a double-lung transplant in 2009 at Loyola University Health System. "I named my new lungs Lucy and Ethel to welcome them," said the humorous and outgoing Chicagoan. "Lucy acts up once in a while but they are both working fine."

26 Apr 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

CSL Behring commits donations to World Federation of Hemophilia GAP program

To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year.

17 Apr 2012

Novel technology to grow new primordial lung progenitors

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have derived a population of pure lung and thyroid progenitor cells in vitro that successfully mimic the developmental milestones of lung and thyroid tissue formation.

6 Apr 2012

HSP27 protein can indicate lung damage during early stages of COPD

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In Austria alone, there are between 500,000 and 600,000 sufferers; around ninety per cent of cases are the result of smoking. Now, under the leadership of Hendrik Jan Ankersmit, a research team from the University Department of Surgery at MedUni Vienna and the Christian Doppler Laboratory for the Diagnosis and Regeneration of Heart and Thorax Diseases has discovered a protein marker in the blood that can already indicate lung damage during the early stages of COPD, before a decrease in lung volume is detected by a pulmonary function test.

5 Apr 2012

Albumin best choice for prevention of circulatory dysfunction in cirrhotic patients

Administration of albumin reduces morbidity and mortality in cirrhotic patients undergoing large-volume paracentesis due to severe ascites, according to a new meta-analysis published online today in Hepatology, the official journal of the American Association for the Study of Liver Diseases.

29 Mar 2012

Novartis' Arcapta Neohaler now available in the U.S. for COPD treatment

Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide.

20 Mar 2012

Do we age as a consequence of being protected against cancer?

The role of one of our genes which protects us from cancer but could also cause us to age will be explained in a lecture at the University of Leicester.

8 Mar 2012